Table 1. Clinical Features of Samples*.
| All Subjects | Discovery | Validation Set 1 | Validation Set 2 | |
|---|---|---|---|---|
| Subjects | 46 | 16 | 18 | 12 |
| Age at Diagnosis | 59.3 (49.9–70.4) | 57.6 (50.4–69.0) | 60.7 (49.9–70.4) | 60.3 (49.9–70.4) |
| PSA (ng/mL) | 8.39 (0.73–49.4) | 7.51 (2.3–18.22) | 8.63 (0.73–49.4) | 6.70 (3.48–16.7) |
| BMI (kg/m2) | 28.1 (33.5–21.8) | 25.9 (19.4–32.1) | 29.3 (21.8–39.1) | 28.1 (21.8–33.5) |
| Ethnicity | ||||
| Non-Hispanic White | 27 | 8 | 10 | 9 |
| African American | 18 | 7 | 8 | 3 |
| Hispanic | 1 | 1 | 0 | 0 |
| Pathologic Stage at Prostatectomy | ||||
| pT2a | 2 | 0 | 2 | 0 |
| pT2c | 33 | 12 | 10 | 11 |
| pT3a | 8 | 4 | 3 | 1 |
| pT3b | 3 | 0 | 3 | 0 |
| Gleason Sum Score | 6.9 | 7.0 | 6.8 | |
| 3 + 3 | 7 | 1 | 2 | 4 |
| 3 + 4 | 30 | 13 | 12 | 5 |
| 4 + 3 | 7 | 2 | 3 | 2 |
| 4 + 4 | 1 | 0 | 0 | 1 |
| 3 + 5 | 0 | 0 | 0 | 0 |
| 4 + 5 | 0 | 0 | 0 | 0 |
| 5 + 5 | 0 | 0 | 0 | 0 |
*The table shows age and range of subjects at the time of prostate cancer diagnosis, PSA level and range for the assay closest to the time of prostatectomy, and BMI and range at the time of diagnosis. At prostatectomy, the number of subjects with the pathologic stage and the number of subjects with each Gleason sum score are provided.